Eli Lilly and Company (LLY)
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Lilly (LLY) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Eli Lilly Weight-Loss Pill Trial Disappoints, Offsetting Solid Profit and Sales
Ely Lilly (LLY) shares sank 14% Thursday when the pharmaceutical firm reported disappointing results from a late-stage study of its experimental obesity pill. The news offset Lilly's strong quarterly results.
Eli Lilly shares tumble on disappointing weight loss drug trial data
Eli Lilly and Co (NYSE:LLY) shares fell more than 10% at the market open as disappointing late-stage trial data for the company's oral weight loss drug orforglipron drew focus from strong second quarter earnings and raised full-year guidance. The trial showed orforglipron users saw an average weight loss of 12.4% over 72 weeks, which was positive and met the primary endpoint.
Eli Lilly (LLY) Q2 Earnings and Revenues Surpass Estimates
Eli Lilly (LLY) came out with quarterly earnings of $6.31 per share, beating the Zacks Consensus Estimate of $5.61 per share. This compares to earnings of $3.92 per share a year ago.
Eli Lilly's oral weight-loss pill didn't work so well, and the stock is plunging
Stock was heading for biggest one-day selloff in 26 years
Eli Lilly raises full-year profit forecast on weight-loss drug strength
Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo Nordisk's Wegovy.
Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason.
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.
Eli Lilly: Sell LLY Stock Ahead of Its Earnings?
Eli Lilly (NYSE:LLY) is set to release its earnings on Thursday, August 7, 2025. In the past, Eli Lilly's stock has displayed a pattern of negative one-day returns following earnings announcements.
Insights Into Lilly (LLY) Q2: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Lilly (LLY) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Should You Buy, Sell or Hold Lilly Stock Ahead of Q2 Earnings?
LLY eyes Q2 growth on Mounjaro and Zepbound momentum, but pricing pressure and rising competition test its edge.
Trim Your AI Stocks And Buy Eli Lilly
AI and semiconductor stocks are too expensive right now. Don't buy them now, trim your high-tech positions, and buy healthcare stocks like Eli Lilly and Company. LLY is a hyper-growth-at-a-reasonable-price play. A 30% 12-month return is reasonable to anticipate. It is not too early to buy healthcare stocks; it will just require patience. I'd rather leave the party first and miss the traffic than move with the crowd.
